Is HCMV vaccine an unmet need? The state of art of vaccine development

Abstract

Congenital HCMV infection is the most frequent congenital infection, with an incidence of 0.2-2.5% among all live births. About 11% of infected newborns show symptoms at birth, including hepatosplenomegaly, thrombocytopenia, neurologic involvement, hearing impairment and visual deficit. Moreover, 5-25% of the asymptomatic congenital HCMV-infected neonates will develop sequelae over months or even years. The relevant social burden, the economic costs of pre-natal screening, post-natal diagnosis, follow-up and possible therapy, although still limited, are the major factors to be considered. Several types of vaccines have been explored in order to develop an effective and safe HCMV vaccine: live attenuated, subunit, vectored, peptide, DNA, and subviral ones, but none are available for use. This review illustrates the different vaccine types studied to date, focusing on the possible vaccination strategy to be implemented once the HCMV vaccine is available, in terms of target population. Copyright © by BIOLIFE, s.a.s.